ICPT - Intercept Pharma GAAP EPS of -$0.50 misses by $0.26 revenue of $77.22M misses by $0.86M

March, 02 2023 07:05 AM Intercept Pharmaceuticals Inc.

Intercept Pharma press release ( NASDAQ: ICPT ): Q4 GAAP EPS of -$0.50 misses by $0.26 .
Revenue of $77.22M (+12.5% Y/Y) misses by $0.86M .
As of December 31, 2022, Intercept had cash, cash equivalents, restricted cash, and investment debt securities available for sale of $490.9 million. As of December 31, 2021, Intercept had cash, cash equivalents, restricted cash, and investment debt securities available for sale of approximately $427.8 million.
2023 Outlook:
Intercept is announcing 2023 Ocaliva net sales guidance of $310 million to $340 million, as compared to 2022 Ocaliva U.S. net sales of $285.7 million.
In addition, the company is announcing 2023 non-GAAP adjusted operating expense guidance of $360 million to $390 million.

For further details see:

Company Name:	Intercept Pharmaceuticals Inc.
Stock Symbol:	ICPT
Market:	NASDAQ
Website:	interceptpharma.com